Boston Scientific to Buy Full Control of Sadra Medical

Boston Scientific Corp. agreed to acquire closely held Sadra Medical Inc. for as much as $386 million to compete in the $2.1 billion market for implantable cardiac valves that don’t require open-heart surgery.

Boston Scientific, the owner of 14 percent of Sadra, will pay $193 million upfront, with additional payments of as much as $193 million for certain milestones, the companies said in a statement. The purchase fits within a Boston Scientific goal, announced today by Chief Executive Ray Elliott, to expand in asthma, diabetes, obesity and heart valve disorders.